why choose us

300×250 Ad Slot

Research Article: Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis

Date Published: 2023-12-06

Abstract:
To assess cigarette smoking’s effects on efficacy of the preferential Janus kinase (JAK) 1 inhibitor filgotinib and drug persistence in patients with rheumatoid arthritis (RA).

Introduction:
Cigarette smoking is an important risk factor for the development of rheumatoid arthritis (RA) [1] and is associated with higher RA disease activity [2]. Furthermore, smokers with RA have been described as less likely to respond to some treatments and more likely to discontinue or switch treatments compared with non-smokers [3,4,5,6]. Filgotinib, an oral preferential Janus kinase (JAK) 1 inhibitor, was evaluated in three phase 3 clinical studies in adults with moderately to severely active RA [7,8,9]. In subgroup…

Read more

300×250 Ad Slot